Novartis announced recently that the US Food and Drug Administration (FDA) approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic). These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy).
Pluvicto
is the first FDA-approved targeted radioligand therapy (RLT) for eligible
patients with mCRPC that combines a targeting compound (ligand) with a
therapeutic radioisotope (a radioactive particle). Pluvicto is expected to be
available to physicians and patients within weeks.
To
read more please visit:
Source: Novarrtis